Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Genmab A/S
  6. News
  7. Summary
    GMAB   DK0010272202


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Genmab A/S : Investor Presentation - September 2021

09/22/2021 | 05:02am EDT



Improving Lives

Investor Presentation

September 2021

© Genmab For Investor audience only. Not for public information or use. Not for promotional use.

Forward looking statement

This presentation contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the

outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Further, certain forward looking statements are based upon assumptions of future events which may not prove to be accurate. The forward looking statements in this document speak only as at the date of this presentation. Genmab does not undertake any obligation to update or revise forward looking statements in this presentation nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

© Genmab


For Investor audience only. Not for public information or use. Not for promotional use.

On the Road to 2025: Evolving Into a Fully Integrated Biotech

Core Purpose

To improve the lives of patients

by creating & developing innovative antibody products

Our Strategy

  • Focus on core competence
  • Turn science into medicine
  • Build a profitable & successful biotech


By 2025, our own product has transformed cancer treatment and we have a pipeline of knock-your-socks off antibodies

Our Core Purpose, Strategy & Vision

Guide Our Work

© Genmab


For Investor audience only. Not for public information or use. Not for promotional use.

Well Positioned for Future Growth

Consistent and solid track record

World-class pipeline & innovation with two potential near-term launches


Strong Financials

with innovators and

to invest in growth

industry leaders


© Genmab


For Investor audience only. Not for public information or use. Not for promotional use.

Consistent, Solid Track Record Fuels Our Growth:

Over 20 Years of Achievements

  • 39 Cumulative INDs since
  • Innovative clinical pipeline: 8
    Genmab owned ≥50%
  • First BLA submission
  • 5 approved therapies that include Genmab's innovation
  • First product on the market: TIVDAK™ (tisotumab vedotin- tftv)*
  • 8 Years of profitability & expanding top line
  • Investing in our capabilities
  • Experienced, international management team
  • Dual-listedin US & DK

© Genmab


*Co-development Genmab and Seagen

For Investor audience only. Not for public information or use. Not for promotional use.


Genmab A/S published this content on 20 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 September 2021 09:01:05 UTC.

ę Publicnow 2021
All news about GENMAB A/S
10/21PRESS RELEASE : Pfizer and BioNTech Announce Phase -3-
10/20Lower rates mean climate costs higher than thought, SF Fed paper says
10/20JOHNSON & JOHNSON : Genmab Announces Net Sales of DARZALEX (daratumumab) for the Third Qua..
10/19GENMAB A/S : Company Announcement - Form 6-K
10/19GENMAB A/S : Darzalex Sales Hit $1.58 Billion In Q3
10/19GENMAB A/S : Announces Net Sales of DARZALEX« (daratumumab) for the Third Quarter of 2021
10/19Genmab Announces Net Sales of DARZALEX« (daratumumab) for the Third Quarter of 2021
10/19Genmab A/S Announced DARZALEX Sales Results for the Third Quarter of 2021
10/18GENMAB A/S : has published its Articles of Association
10/18GENMAB A/S : Janssen Receive Positive Opinion for Lung Cancer Treatment from EU Committee
More news
Analyst Recommendations on GENMAB A/S
More recommendations
Sales 2021 8 091 M 1 263 M 1 263 M
Net income 2021 2 394 M 374 M 374 M
Net cash 2021 14 754 M 2 302 M 2 302 M
P/E ratio 2021 85,0x
Yield 2021 -
Capitalization 195 B 30 472 M 30 459 M
EV / Sales 2021 22,3x
EV / Sales 2022 16,5x
Nbr of Employees 1 029
Free-Float 94,9%
Duration : Period :
Genmab A/S Technical Analysis Chart | GMAB | DK0010272202 | MarketScreener
Technical analysis trends GENMAB A/S
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 2 985,00 DKK
Average target price 2 804,30 DKK
Spread / Average Target -6,05%
EPS Revisions
Managers and Directors
Jan G. J. van de Winkel President & Chief Executive Officer
Anthony Pagano Chief Financial Officer & Executive Vice President
Deirdre P. Connelly Chairman
Tahamtan Ahmadi Chief Medical Officer & Executive Vice President
Anthony Mancini Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
GENMAB A/S21.19%30 472
BIONTECH SE261.78%71 229
WUXI APPTEC CO., LTD.24.08%64 399